Controlling the activity of specific genes in the laboratory through the editing of their epigenetic marks is now a reality thanks to the CRISPR technology. A team from the Josep Carreras Leukemia Research Institute has demonstrated that it is possible to precisely control the methylation status of one of the key genes involved in controlling the inflammatory response (IL1RN), thereby modifying how the cell responds to external stimuli. With this finding, the development of innovative therapies based on epigenome editing to tackle inflammatory diseases, including myeloid leukemia, is one step closer.
This article was originally published on MedicalXpress.com
